Skip to Main Content

Good morning, everyone, and how are you today? We are just fine, thank you, especially since a warm and shiny sun is enveloping the satellite Pharmalot campus in New England. However, we must forage more diligently for delicious cups of stimulation, but we will persevere. Nonetheless, our ability to uncover items of interest remains intact. So here they are. As always, we hope your day is splendid and productive, and that you conquer the world. And do drop us a line if you run across any secrets. …

Sanofi (SNY) was aware of the risks of its Dengvaxia vaccine in 2015, but did not inform the Philippine governmentTech2 writes. Nela Charade Puno, the director of the Philippines Food and Drug Administration, told a House committee that an FDA special working group on Dengvaxia reviewed documents submitted by Sanofi to Singapore, which allowed commercial sale of the dengue vaccine in October 2016. Puno said Sanofi already informed Singapore that Dengvaxia will lead a person to develop severe dengue if not infected with the virus before vaccination.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.